Skip to content

Effects of Cannabis Species Labeling and Marketing on Perceptual, Subjective and Objective Use Outcomes (Aim 2 Study)

Effects of Cannabis Species Labeling and Marketing on Perceptual, Subjective and Objective Use Outcomes (Aim 2 Study)

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07513337
Enrollment
3035
Registered
2026-04-07
Start date
2026-04-15
Completion date
2026-07-16
Last updated
2026-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cannabis Use

Keywords

labeling and marketing, cannabis use, product perception

Brief summary

This study looks at how cannabis product label and marketing claims affect product perceptions, use expectancies, and use intentions among inexperienced and experienced cannabis users. Participants will answer online survey questions on their perceptions of a cannabis product advertisement.

Detailed description

This study aims to specify how product label and marketing claims affect product perceptions, use expectancies, and use intentions among cannabis users. A randomized 4 (Sativa, Indica, Hybrid, no strain label) x 3 (energizing, sedative, no claim) online experiment will be conducted with a sample of adults from states that have legalized adult cannabis recreational use. Our main research questions are: (1) Do label and marketing claim affect (a) harm perceptions, (b) subjective effects expectancies (e.g., arousal, sedation), (c) willingness to use, and (d) willingness to use during daily activities (e.g., driving)? and (2) Do label and marketing claim interact to affect product perceptions, use expectancies, and use intentions?

Interventions

OTHERStrain label

Presentation of strain label on cannabis advertising material

OTHERClaim

Presentation of claim on cannabis advertising material

Sponsors

Johns Hopkins Bloomberg School of Public Health
Lead SponsorOTHER
National Institute on Drug Abuse (NIDA)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age = 21+ * Live in in a US state (or Washington D.C.) in which recreational cannabis sale is legal and implemented * For inexperienced users: lifetime cannabis use \>1 \& \<= 10 * For experienced users: lifetime cannabis use\>10 \& \<100, past month cannabis use\>0

Exclusion criteria

* Under age 21 * Does not live in a US state (or Washington D.C.) in which recreational cannabis sale is legal and implemented * Lifetime cannabis use \>=100 times * Lifetime cannabis use \<1 time * Lifetime cannabis use\>10 \& \<100 AND past month cannabis use=0

Design outcomes

Primary

MeasureTime frameDescription
Harm perception - One time useImmediately after viewing adHow harmful participant perceives the product to be after one time use. Participants will answer a survey item, In your opinion, what is the level of risk to one's health from using the product you just viewed one time?; with response options ranging from 0-Very low risk to 4-Very high risk.
Harm perception - Daily useImmediately after viewing adHow harmful participant perceives the product to be with daily use. Participants will answer a survey item, In your opinion, what is the level of health risk from using the product you just viewed on a daily basis?; with response options ranging from 0-Very low risk to 4-Very high risk.
Expectancy effectsImmediately after viewing adEffects participant expects to feel after using the product. Participants will answer a survey item, Please rate the extent to which you expect to feel each of the following effects \[paranoid; panicked; fearful; anxious; suspicious; like my heart is racing; sluggish; drowsy; out of it; slow; lazy; excited; heightened senses; sociable; creative; wise; in tune with nature; focused; productive; sleepy; happy; euphoric; calm; relaxed; pain-free\] after using the product you just viewed; with response options ranging from 0-not at all to 10-extremely.
Willingness to useImmediately after viewing adHow willing participant is to use the product. Participants will answer a survey item, How willing would you be to use the product you just viewed?; with response options ranging from 0-Not at all willing to 4-Very willing.
Willingness to use during daily activitiesImmediately after viewing adHow willing participant is to use the product during daily activities. Participants will answer a survey item, How willing would you be to use the product you just viewed if you \[wanted to concentrate; wanted to relax; wanted to socialize; wanted to do a creative activity (e.g., art, music); wanted to feel happier; wanted to relieve medical symptoms/treat a medical condition/mental health condition; were going to drive a car in the next 30 minutes; were going to bed in the next 30 minutes; were planning to stay home for the next several hours; were going to work in the next 30 minutes; were at a party\]?; with response options ranging from 0-Not at all willing to 4-Very willing.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORMeghan Moran, PhD

Johns Hopkins University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 18, 2026